1. Home
  2. NRIX vs PD Comparison

NRIX vs PD Comparison

Compare NRIX & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.85

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo PagerDuty Inc.

PD

PagerDuty Inc.

N/A

Current Price

$7.58

Market Cap

987.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
NRIX
PD
Founded
2009
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
987.5M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
NRIX
PD
Price
$15.85
$7.58
Analyst Decision
Strong Buy
Buy
Analyst Count
13
9
Target Price
$29.46
$17.00
AVG Volume (30 Days)
694.1K
3.5M
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.71
EPS
N/A
1.73
Revenue
$76,987,000.00
$467,499,000.00
Revenue This Year
N/A
$8.16
Revenue Next Year
$26.32
$3.75
P/E Ratio
N/A
$4.60
Revenue Growth
99.31
8.54
52 Week Low
$8.18
$6.18
52 Week High
$22.50
$19.70

Technical Indicators

Market Signals
Indicator
NRIX
PD
Relative Strength Index (RSI) 46.92 42.83
Support Level $15.62 $6.18
Resistance Level $16.49 $16.48
Average True Range (ATR) 0.78 0.37
MACD 0.05 0.29
Stochastic Oscillator 65.87 74.40

Price Performance

Historical Comparison
NRIX
PD

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

Share on Social Networks: